Sunday, October 25, 2009
Investors with a long-term perspective can accumulate the stock of Divi’s Laboratories, which is a key player in the global pharmaceutical outsourcing market.
The company has well-established working relationships with a number of the top 20 global innovator firms. Its healthy return ratios, strong position in niche segments and the likely revenue trigger from its entry into the nutraceuticals segment are also positives.
Its valuations also appear reasonable given the growth potential. At the current market price of Rs 565, the stock trades at about 16 times its likely FY11 per share earnings.
Source: BL Research
Get Started Now 
Posts
3 Post Your Response Here:
Leave Your Address in the Comment Field, the Registration Details will be sent to your Email Address.
Name:
Email Id:
Place:
Phone/Mobile No:
Javeriya aziz
juvi.aziz@gmail.com
Hyderabad
9703352330
riqwestwd sir
name :name bavisa balkrushan j
Id;bavisabj@Gmail.com
place:rajkot
mobil no:9727697975
Post a Comment